Artigos de revistas: "Antineoplastic agents"

1

Carlson, Patricia A. "Antineoplastic agents". Critical Care Nursing Quarterly 18, n.º 4 (fevereiro de 1996): 1–15. http://dx.doi.org/10.1097/00002727-199602000-00002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Menta, Ernesto, e Manlio Palumbo. "Novel antineoplastic agents". Expert Opinion on Therapeutic Patents 7, n.º 12 (dezembro de 1997): 1401–26. http://dx.doi.org/10.1517/13543776.7.12.1401.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Menta, Ernesto, e Manlio Palumbo. "Antineoplastic agents 1998". Expert Opinion on Therapeutic Patents 8, n.º 12 (dezembro de 1998): 1627–72. http://dx.doi.org/10.1517/13543776.8.12.1627.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Pettit, G. R., Y. Kamano, R. Aoyagi, C. L. Herald, D. L. Doubek, J. M. Schmidt e J. J. Rudloe. "Antineoplastic agents 100". Tetrahedron 41, n.º 6 (janeiro de 1985): 985–94. http://dx.doi.org/10.1016/s0040-4020(01)96466-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Bukowski, Ronald M. "Novel antineoplastic agents". Current Oncology Reports 2, n.º 1 (janeiro de 2000): 9–10. http://dx.doi.org/10.1007/s11912-000-0004-1.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Hong, Samuel J., Edward C. Li, Linda M. Matusiak e Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016". Journal of Oncology Practice 14, n.º 11 (novembro de 2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Texto completo da fonte

Resumo:

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of January 1, 2011, to December 31, 2016. Actual expenditures were totaled by health care sector and calendar year, then adjusted for medical-cost inflation to 2016 dollars. Growth was calculated as the percentage increase from the previous year. Results: Total expenditures of antineoplastic agents across all channels grew from $26.8 billion in 2011 to $42.1 billion in 2016. Antineoplastic spending increased 12.2% in 2016 (compared with the previous year), followed by 15.6% in 2015, 13.4% in 2014, 6.3% in 2013, and 0.4% in 2012. Throughout the study period, 96.5% of total antineoplastic expenditures occurred within clinics, mail-order pharmacies, nonfederal hospitals, and retail pharmacies. Conclusion: Antineoplastic expenditures are expected to increase because of continuing development and approval of costly targeted cancer therapies. Cost containment and utilization management strategies must be balanced so as not to restrict access or disrupt innovation. Future policies should focus on ensuring safe and appropriate use of antineoplastics while balancing long-term drug costs.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

DOLL, DONALD C., Q. SCOT RINGENBERG e JOHN W. YARBRO. "Antineoplastic Agents and Pregnancy". Obstetrical & Gynecological Survey 45, n.º 6 (junho de 1990): 376. http://dx.doi.org/10.1097/00006254-199006000-00008.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Pettit, George R., Noeleen Melody e Jean-Charles Chapuis. "Antineoplastic Agents. 605. Isoquinstatins". Journal of Natural Products 81, n.º 3 (19 de setembro de 2017): 451–57. http://dx.doi.org/10.1021/acs.jnatprod.7b00352.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Hussain, M. A. ha, A. N. toinette J. Wozniak e M. A. rk B. Edelstein. "Neurotoxicity of antineoplastic agents". Critical Reviews in Oncology/Hematology 14, n.º 1 (fevereiro de 1993): 61–75. http://dx.doi.org/10.1016/1040-8428(93)90006-p.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Castells, M. "Hypersensitivity to Antineoplastic Agents". Current Pharmaceutical Design 14, n.º 27 (1 de setembro de 2008): 2892–901. http://dx.doi.org/10.2174/138161208786369803.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Fernandez, F. "Psychotoxicity from antineoplastic agents." Journal of Clinical Oncology 5, n.º 2 (fevereiro de 1987): 319–20. http://dx.doi.org/10.1200/jco.1987.5.2.319.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

McNabb, Lorna, Eva Metrot, Micaela Ferrington, Bruce Sunderland, Richard Parsons, Tandy-Sue Copeland, Siobhan Corscadden, Selina Tong e Petra Czarniak. "Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic". PLOS ONE 19, n.º 6 (13 de junho de 2024): e0304011. http://dx.doi.org/10.1371/journal.pone.0304011.

Texto completo da fonte

Resumo:

Background Oral antineoplastic agents have caused a paradigm shift in cancer treatment, however, they produce many unique challenges. Although oral antineoplastics can have complex administration regimes, low adherence rates and high possibilities of drug-drug interactions, they are administered unsupervised at home. Cancer services pharmacists have the required skillsets to improve patient outcomes associated with oral antineoplastic treatment by increasing patient health literacy, improving concordance and optimising administration protocols. Aim To evaluate patients’ perceptions, experiences and overall satisfaction with dedicated clinical pharmacist consultations in patients treated with oral antineoplastic agents at a major public hospital. Method In this retrospective cross-sectional study at a quaternary hospital in Western Australia, data were collected by a paper questionnaire (mailed in March 2022) to a random sample of 191 patients initiated on oral antineoplastic drugs between January 2021 and February 2022. Demographics, prescribed antineoplastic drug/s, cancer type data were collected including using 5-point Likert scale questions assess patients’ overall satisfaction with the clinical pharmacist consultations. Results The questionnaire response rate was 27.7% (52/188) (mean age 63.2 years; 57.5% female). Most patients (42/52; 80.8%) were satisfied with pharmacist consultations, trusted the pharmacist’s advice (45/52; 86.5%), considered that the pharmacist improved their understanding of how to manage side effects (43/52; 82.7%) and they provided an important service in outpatient care (45/52; 86.5%). Conclusion Overall, patients reported positive perceptions, experiences, and satisfaction with the cancer services pharmacist counselling services during their oral antineoplastic treatment.

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Yamashiro, Yoshiko, Yoshikazu Fukuoka, Akira Yotsuji, Takashi Yasuda, Isamu Saikawa e Yasushi Ueda. "Interactions of antimicrobial agents and antineoplastic agents". Journal of Antimicrobial Chemotherapy 18, n.º 6 (1986): 703–8. http://dx.doi.org/10.1093/jac/18.6.703.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Melamed, Andra J., e Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents". Drug Intelligence & Clinical Pharmacy 22, n.º 3 (março de 1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Texto completo da fonte

Resumo:

Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to the present, limiting the search to English-language articles. This article provides a comprehensive bibliography on the handling of antineoplastic agents.

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Garcia, Gwenalyn, e Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy". Journal of Oncology Pharmacy Practice 23, n.º 2 (23 de junho de 2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Texto completo da fonte

Resumo:

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Sutton, Karen, Tara B. Sanft, Tish M. Knobf e Izuchukwu K. Ibe. "Musculoskeletal Effects of Antineoplastic Agents". Journal of the American Academy of Orthopaedic Surgeons 27, n.º 22 (novembro de 2019): 834–39. http://dx.doi.org/10.5435/jaaos-d-17-00713.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

PATTERSON, WILLIAM B. "Occupational Hazard from Antineoplastic Agents". Annals of Internal Medicine 103, n.º 6_Part_1 (1 de dezembro de 1985): 965. http://dx.doi.org/10.7326/0003-4819-103-6-965_2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Graeve, Catherine Utecht, Patricia Marie McGovern, Bruce Alexander, Timothy Church, Andrew Ryan e Martha Polovich. "Occupational Exposure to Antineoplastic Agents". Workplace Health & Safety 65, n.º 1 (7 de outubro de 2016): 9–20. http://dx.doi.org/10.1177/2165079916662660.

Texto completo da fonte

Resumo:

Approximately 8 million health care workers are unnecessarily exposed to highly toxic drugs used to treat cancer; antineoplastic drugs can contribute to negative health effects for these workers. The drugs have been detected in the urine of workers and on the floors and counters of worksites. Safety precautions that could reduce the risk of exposure are underutilized. This cross-sectional study of 163 oncology health care workers used a survey to measure workplace and individual factors, and environmental sampling to measure surface contamination. The study objective was to identify potential exposures to antineoplastic drugs and factors influencing safety behavior. Personal protective equipment (PPE) use was lower than recommended; unit of employment was significantly associated with PPE use. Chemical residue from antineoplastic drugs was found, revealing potential exposures. Workplace safety must be a higher organizational priority. The contamination of common work areas where PPE use is not expected was of utmost concern.

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu e Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents". American Journal of Clinical Oncology 26, n.º 2 (abril de 2003): 121–23. http://dx.doi.org/10.1097/00000421-200304000-00003.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Shahab, Nasir, Syed Haider e Donald C. Doll. "Vascular Toxicity of Antineoplastic Agents". Seminars in Oncology 33, n.º 1 (fevereiro de 2006): 121–38. http://dx.doi.org/10.1053/j.seminoncol.2005.11.006.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Fortner, Clarence L., e Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents". Journal of Pharmacy Practice 4, n.º 1 (fevereiro de 1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Texto completo da fonte

Resumo:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information is submitted to the FDA for their review and approval for marketing. Prior to that approval, the FDA may approve broader distribution of the drug for specific indications under a Treatment Investigational New Drug (IND) or the National Cancer Institute's (NCI) group C mechanism. Pharmacists can play a unique role during development of the Treatment IND by contributing to design of the protocol and screening patient qualifications. The investigator of the clinical trial has responsibility for the conduct of the clinical trial and must comply with FDA regulations and sponsor policies. This is a US government work. There are no restrictions on its use.

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Chitambar, Christopher R. "Gallium compounds as antineoplastic agents". Current Opinion in Oncology 16, n.º 6 (novembro de 2004): 547–52. http://dx.doi.org/10.1097/01.cco.0000142071.22226.d2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Hamnvik, O. P. R., P. R. Larsen e E. Marqusee. "Thyroid Dysfunction from Antineoplastic Agents". JNCI Journal of the National Cancer Institute 103, n.º 21 (18 de outubro de 2011): 1572–87. http://dx.doi.org/10.1093/jnci/djr373.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Grangé, Steven, e Paul Coppo. "Thrombotic microangiopathies and antineoplastic agents". Néphrologie & Thérapeutique 13 (abril de 2017): S109—S113. http://dx.doi.org/10.1016/j.nephro.2017.01.016.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Pettit, George R., Noeleen Melody e Jean-Charles Chapuis. "Antineoplastic Agents. 606. The Betulastatins". Journal of Natural Products 81, n.º 3 (5 de janeiro de 2018): 458–64. http://dx.doi.org/10.1021/acs.jnatprod.7b00536.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Pettit, George R., Noeleen Melody e Jean-Charles Chapuis. "Antineoplastic Agents. 607. Emetine Auristatins". Journal of Natural Products 83, n.º 5 (23 de abril de 2020): 1571–76. http://dx.doi.org/10.1021/acs.jnatprod.0c00031.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Pettit, G. R., S. B. Singh, A. Goswami e R. A. Nieman. "Antineoplastic agents 157. Quassia kerstingII1". Tetrahedron 44, n.º 11 (janeiro de 1988): 3349–54. http://dx.doi.org/10.1016/s0040-4020(01)85969-x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Pettit, George R., Venkatswamy Gaddamidi, Delbert L. Herald, Sheo Bux Singh, Gordon M. Cragg, Jean M. Schmidt, Fred E. Boettner, M. Williams e Yoneo Sagawa. "Antineoplastic Agents, 120. Pancratium littorale". Journal of Natural Products 49, n.º 6 (novembro de 1986): 995–1002. http://dx.doi.org/10.1021/np50048a005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Pettit, George R., Gordon M. Cragg, Sheo Bux Singh, James A. Duke e Dennis L. Doubek. "Antineoplastic Agents, 162. Zephyranthes candida". Journal of Natural Products 53, n.º 1 (janeiro de 1990): 176–78. http://dx.doi.org/10.1021/np50067a026.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Rogers, Bonnie. "Antineoplastic Agents Action and Toxicities". AAOHN Journal 34, n.º 11 (novembro de 1986): 530–38. http://dx.doi.org/10.1177/216507998603401104.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Bodet, C. A., J. H. Jorgensen e D. J. Drutz. "Antibacterial activities of antineoplastic agents." Antimicrobial Agents and Chemotherapy 28, n.º 3 (1 de setembro de 1985): 437–39. http://dx.doi.org/10.1128/aac.28.3.437.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Pettit, George R., Noeleen Melody, Michael Simpson, Michael Thompson, Delbert L. Herald e John C. Knight. "Antineoplastic Agents 500. Narcistatin†,1". Journal of Natural Products 66, n.º 1 (janeiro de 2003): 92–96. http://dx.doi.org/10.1021/np020225i.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu e Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents". American Journal of Clinical Oncology 26, n.º 2 (abril de 2003): 121–23. http://dx.doi.org/10.1097/01.coc.0000017088.74592.96.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Borch, Richard F., e Thomas J. Montine. "Renal toxicity of antineoplastic agents". Toxicology Letters 53, n.º 1-2 (setembro de 1990): 93–96. http://dx.doi.org/10.1016/0378-4274(90)90100-z.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Weiss, Raymond B., e James R. Baker. "Hypersensitivity reactions from antineoplastic agents". Cancer and Metastasis Reviews 6, n.º 3 (novembro de 1987): 413–32. http://dx.doi.org/10.1007/bf00144273.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Johnson, Candace S. "Modulation of chemotherapy antineoplastic agents with biologic agents". Current Opinion in Oncology 4, n.º 6 (dezembro de 1992): 1108. http://dx.doi.org/10.1097/00001622-199212000-00016.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Hall, Amy L., Paul A. Demers, George Astrakianakis, Calvin Ge e Cheryl E. Peters. "Estimating National-Level Exposure to Antineoplastic Agents in the Workplace: CAREX Canada Findings and Future Research Needs". Annals of Work Exposures and Health 61, n.º 6 (8 de junho de 2017): 656–58. http://dx.doi.org/10.1093/annweh/wxx042.

Texto completo da fonte

Resumo:

AbstractObjectives:Occupational exposure to antineoplastic agents occurs in various environments and is associated with increased cancer risk and adverse reproductive outcomes. National-level information describing the location and extent of occupational exposure to antineoplastic agents is unavailable in Canada and most other countries. CAREX Canada aimed to estimate the prevalence and relative levels of occupational exposures to antineoplastic agents across work setting, occupation, and sex.Methods:‘Exposure’ was defined as any potential for worker contact with antineoplastic agents. Baseline numbers of licensed workers were obtained from their respective professional bodies. For unlicensed workers, Census data or data extrapolated from human resources reports (e.g., staffing ratios) were used. Prevalence was estimated by combining population estimates with exposure proportions from peer-reviewed and grey literature. Exposure levels (classified as low, moderate, and high) by occupation and work setting were estimated qualitatively by combining estimates of contact frequency and exposure control practices.Results:Approximately 75000 Canadians (0.42% of the total workforce) are estimated as occupationally exposed to antineoplastic agents; over 75% are female. The largest occupational group exposed to antineoplastic agents is community pharmacy workers, with 30200 exposed. By work setting, 39000 workers (52% of all exposed) are located in non-hospital settings; the remaining 48% are exposed in hospitals. The majority (75%) of workers are in the moderate exposure category.Conclusions:These estimates of the prevalence and location of occupational exposures to antineoplastic agents could be used to identify high-risk groups, estimate disease burden, and target new research and prevention activities. The limited secondary data available for developing these estimates highlights the need for increased quantitative measurement and documentation of antineoplastic agent contamination and exposure, particularly in work environments where use is emerging.

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Beckwith, M. Christina, e Linda S. Tyler. "Preventing Medication Errors with Antineoplastic Agents, Part 1". Hospital Pharmacy 35, n.º 5 (maio de 2000): 511–26. http://dx.doi.org/10.1177/001857870003500502.

Texto completo da fonte

Resumo:

Goal — The goal of this program is to present practical ways to prevent medication errors with antineoplastic agents, identify common types of medication errors, and describe a system for reducing the incidence of medication errors and responding appropriately to antineoplastic medication errors. Objectives — At the completion of this program, the participant will be able to: 1. Describe the scope and impact of medication errors 2. Define common terms used in medication error literature. 3. List four common types of prescribing errors made with anti-neoplastic agents. 4. Identify steps where medication errors may occur during the drug ordering, preparation, and administration process. 5. Describe ways to prevent errors at each step of the medication use process. 6. Recommend a procedure for reporting and monitoring antineoplastic medication errors within the institution. 7. Describe a system for the non-punitive management of antineoplastic medication errors in health care systems.

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Zhang, Hai-Long, e Yiqian Li. "Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis". Pharmaceutical Patent Analyst 10, n.º 2 (março de 2021): 73–82. http://dx.doi.org/10.4155/ppa-2021-0004.

Texto completo da fonte

Resumo:

Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents, and to better demonstrate recent developments for patents concerning drugs for osteoporosis, we conducted an analysis of US patents. The results indicated that there was a good correlation between agents for osteoporosis and antineoplastic agents, which indicated that numerous anti-osteoporosis agents displayed antineoplastic activities. Our study was the first one to provide new evidence, through comprehensive analysis, for a correlation between anti-osteoporosis agents and anticancer agents. The present study may open new avenues for developing anticancer drugs and expanding the application role of anti-osteoporosis agents.

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Boschi, Rita, e Elena Rostagno. "Extravasation of antineoplastic agents: prevention and treatments". Pediatric Reports 4, n.º 3 (1 de agosto de 2012): 28. http://dx.doi.org/10.4081/pr.2012.e28.

Texto completo da fonte

Resumo:

The extravasation of antineoplastic agents is an unwanted and distressing situation that can easily occur. It may cause severe and irreversible local injuries. Left untreated, vesicant chemotherapy extravasation can potentially cause tissue necrosis, functional impairment and permanent disfigurement. This article provides a review of current literature regarding recommendations on the prevention and treatment of extravasation of antineoplastic agents.

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

&NA;. "Antineoplastic agents can cause allergic reactions". Reactions Weekly &NA;, n.º 428 (novembro de 1992): 4. http://dx.doi.org/10.2165/00128415-199204280-00008.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

&NA;. "Pharmacokinetic drug interactions with antineoplastic agents". Drugs & Therapy Perspectives 5, n.º 9 (maio de 1995): 12–14. http://dx.doi.org/10.2165/00042310-199505090-00005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

BATRA, JANENDRA K., CHII M. LIN, ERNEST HAMEL, LEONARD JURD e LARRY J. POWERS. "New Antineoplastic Agents with Antitubulin Activity". Annals of the New York Academy of Sciences 466, n.º 1 Dynamic Aspec (junho de 1986): 785–87. http://dx.doi.org/10.1111/j.1749-6632.1986.tb38459.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

McDiarmid, Melissa, e Thomas Egan. "Acute Occupational Exposure to Antineoplastic Agents". Journal of Occupational and Environmental Medicine 30, n.º 12 (dezembro de 1988): 984–87. http://dx.doi.org/10.1097/00043764-198812000-00020.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Dimopoulou, I., A. Bamias, P. Lyberopoulos e M. A. Dimopoulos. "Pulmonary toxicity from novel antineoplastic agents". Annals of Oncology 17, n.º 3 (março de 2006): 372–79. http://dx.doi.org/10.1093/annonc/mdj057.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Delitheos, A., I. Karavokyros e E. Tiligada. "Response ofSaccharomyces cerevisiaestrains to antineoplastic agents". Journal of Applied Bacteriology 79, n.º 4 (outubro de 1995): 379–83. http://dx.doi.org/10.1111/j.1365-2672.1995.tb03151.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Phillips, Nancy C. "The Safe Handling of Antineoplastic Agents". Journal of Pharmacy Technology 1, n.º 1 (janeiro de 1985): 19–24. http://dx.doi.org/10.1177/875512258500100108.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Davis, Lisa E. "Long-Term Complications of Antineoplastic Agents". Journal of Pharmacy Practice 4, n.º 2 (abril de 1991): 131–50. http://dx.doi.org/10.1177/089719009100400208.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Hercbergs, A. A., D. Garfield, O. Ashur-Fabian e P. J. Davis. "Re: Thyroid Dysfunction from Antineoplastic Agents". JNCI Journal of the National Cancer Institute 104, n.º 5 (30 de janeiro de 2012): 422–23. http://dx.doi.org/10.1093/jnci/djs011.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

P. Torchilin, Vladimir, Leonid Z. Iakoubov e Zeev Estrov. "Antinuclear autoantibodies as potential antineoplastic agents". Trends in Immunology 22, n.º 8 (agosto de 2001): 424–27. http://dx.doi.org/10.1016/s1471-4906(01)01984-6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Artigos de revistas sobre o tema "Antineoplastic agents"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos